Noticias y Actividades de SV Health Investors

SV Health Investors tiene presencia directa en 2 países.

Ver el organigrama con sus 66 ejecutivos principales

Biografías más buscadas en SV Health Investors

• Eugene Hill, Chairman of the Board
• Paul LaViolette, Managing Partner, Medical Technology and Chief Op...
• Greg Madden, Managing Partner, Medtech and Healthcare Growth

Recientes movimientos de ejecutivos en SV Health Investors

• Miles Gerson, se ha incorporado a la empresa como Partner, Therapeutics  (noticia publicada el 24 de marzo de 2026).

Crear su alerta
para seguir los movimientos de los ejecutivos en SV Health Investors.

SV Health Investors tiene 1.643 competidores entre los que se incluyen Griffin Gaming Partners (Estados Unidos), BlackRock (Estados Unidos) y KKR (Estados Unidos).

Popular M&A news in Fondo

• Bridgepoint has announced the acquisition of Obagi Medical Products  (publicado el 4 de junio de 2026).
• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (publicado el 3 de junio de 2026).
• Prime Capital Financial ha Access Capital Partners adquirido (publicado el 2 de junio de 2026).

Otros contactos sugeridos en el sector Fondo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer en Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director en Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director en General Catalyst Partners

Saber más sobre el sector Fondo

Últimos comunicados de prensa de SV Health Investors

• Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial - SV Health Investors
• Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer - SV Health Investors
• Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research - SV Health Investors
• AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid - SV Health Investors
• AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial - SV Health Investors
• Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update - SV Health Investors
• News - SV Health Investors
• SV Health Investors Acquires EpiVax - SV Health Investors
• Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS - SV Health Investors
• Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic - SV Health Investors
• View more press releases Close

Redes sociales sobre SV Health Investors

• SV Health Investors en Wikipedia, Google News y Yahoo Finance
• SV Health Investors en LinkedIn, Twitter y YouTube